A systematic review of intravesical bacillus Calmette-Guérin plus transurethral resection vs transurethral resection alone in Ta and T1 bladder cancer.
about
Intravesical gemcitabine for non-muscle invasive bladder cancerCombined bacterial and viral treatment: a novel anticancer strategyApplications of bacillus Calmette-Guerin and recombinant bacillus Calmette-Guerin in vaccine development and tumor immunotherapyBacillus Calmette-Guérin (BCG) Treatment Failures in Non-Muscle Invasive Bladder Cancer: What Truly Constitutes Unresponsive DiseaseImmunotherapy in urothelial carcinoma: fade or future standard?Review: Application of Nanoparticles in Urothelial Cancer of the Urinary BladderLong-term efficacy results of EORTC genito-urinary group randomized phase 3 study 30911 comparing intravesical instillations of epirubicin, bacillus Calmette-Guérin, and bacillus Calmette-Guérin plus isoniazid in patients with intermediate- and highCould hyaluronic acid (HA) reduce Bacillus Calmette-Guérin (BCG) local side effects? Results of a pilot study.Is intravesical Bacillus Calmette-Guérin therapy superior to chemotherapy for intermediate-risk non-muscle-invasive bladder cancer? An ongoing debate.Gold nanotheranostics: photothermal therapy and imaging of Mucin 7 conjugated antibody nanoparticles for urothelial cancer.Listeria and Salmonella bacterial vectors of tumor-associated antigens for cancer immunotherapy.BCG+MMC trial: adding mitomycin C to BCG as adjuvant intravesical therapy for high-risk, non-muscle-invasive bladder cancer: a randomised phase III trial (ANZUP 1301).Intravesical bacillus Calmette-Guérin is superior to mitomycin C in reducing tumour recurrence in high-risk superficial bladder cancer: a meta-analysis of randomized trials.Best practice in the treatment of nonmuscle invasive bladder cancer.Advances in intravesical therapy of urinary bladder cancer.Predictive biomarkers of bacillus calmette-guérin immunotherapy response in bladder cancer: where are we now?High CD4⁺ T cell density is associated with poor prognosis in patients with non-muscle-invasive bladder cancerMyobacterium bovis peri-prosthetic hip infection with successful prosthesis retention following intravesical BCG therapy for bladder carcinomaCelecoxib for the prevention of nonmuscle invasive bladder cancer: results from a matched control study.Determining optimal maintenance schedules for adjuvant intravesical bacillus Calmette-Guerin immunotherapy in non-muscle-invasive bladder cancer: a systematic review and network meta-analysis.Endourologic treatment of upper urinary tract transitional cell carcinoma.Recent improvements in the detection and treatment of nonmuscle-invasive bladder cancer.Adjuvant intravesical bacillus calmette-guérin therapy and survival among elderly patients with non-muscle-invasive bladder cancerThe Role of Population-Based Observational Research in Bladder CancerManagement of T1 Urothelial Carcinoma of the Bladder: What Do We Know and What Do We Need To Know?Immunotherapy for urothelial carcinoma: current status and perspectives.Bacillus Calmette-Guérin in the management of superficial bladder cancer.Listeriolysin O as a strong immunogenic molecule for the development of new anti-tumor vaccinesThe value of EORTC risk tables in evaluating recurrent non-muscle-invasive bladder cancer in everyday practice.NCCN Guidelines Insights: Bladder Cancer, Version 2.2016.Bacillus Calmette-Guérin treatment of non-muscle invasive bladder cancer.Efficacy of combined intravesical immunotherapy and chemotherapy for non-muscle invasive bladder cancer.Intravesical gemcitabine therapy for non-muscle invasive bladder cancer (NMIBC): a systematic review.Current strategies in the treatment of non-muscle-invasive bladder cancer.Intravesical therapies for bladder cancer - indications and limitations.Current intravesical therapy for non-muscle invasive bladder cancer.The mechanism of action of BCG therapy for bladder cancer--a current perspective.Murine solid tumours as a novel model to study bacterial biofilm formation in vivo.Recombinant bacillus Calmette-Guérin in urothelial bladder cancer immunotherapy: current strategies.Immune therapies in non-muscle invasive bladder cancer.
P2860
Q24203884-75991C86-C1DD-467D-9AB6-EFE3D6179D70Q26773180-A12DF317-108C-45A8-9FBB-50FE5951D0B5Q26798372-F5BFD2C7-BDC3-4460-B78B-DE5104C3AF47Q27011829-194D0CE7-FF1C-4FF4-9783-130A414134A1Q28078284-3052297B-3E52-4DF9-B92C-08EB4EF5BED2Q28386921-034B29D1-7D90-431D-B28B-1D29A29F03B8Q33927694-4F12B269-83D9-40CA-BEAC-732490EE92A8Q34063277-1FE1F259-F874-48BF-88E2-769EE2D91C4CQ35089307-719420FB-26EE-4A6E-9459-6D9698B69C9CQ35193543-3D7A9BA1-74DE-4CE7-B292-CEA9D46560F8Q35543083-052F7501-FC87-4084-B001-54609F2DFE2EQ35642654-C2403380-CB66-4677-B122-538B1919F62AQ35685707-F45CB27A-AA6E-417A-BAFB-768A7B455AC0Q35688392-E46CBFB8-1907-4361-81B8-C88AB358BCF3Q35987762-346760A7-FAFE-4026-BD14-417184389464Q36167778-EE1BF726-4972-4F97-9D89-E7DB1A565FB1Q36261897-C76A990C-4A47-4B62-A258-04DCC956B936Q36276438-3D7030A1-5A92-4363-AFA0-14F87C85E6F4Q36285627-07102FAD-5506-495E-B8E8-734CB641D076Q36362803-5EAE1C98-02AB-44A3-A00E-051EC82A6689Q36395132-7F82E732-F5CC-421C-AE02-C40014678501Q36614005-D60DED5E-3E3A-4C76-9AD7-910742344A37Q36678207-003E041A-7384-49B2-AB4A-2BDAD921A69CQ37053750-479314DD-AF88-4F7C-A5A9-7FCEB78F91D2Q37053829-B66CD183-CE85-4E30-A39A-25CE5768458CQ37137381-F9DDB169-EEF0-4FE4-80EF-0626BC1D82F9Q37197525-87EEB40A-3896-448F-A870-730E7BFD0AC6Q37505374-87B72FD6-A680-4CA4-9FD1-5ED52330E511Q37711567-3B7D4877-D8E0-4DEF-96C1-8C4ABC9FABE8Q37736774-E7935D35-EB3F-44D2-B3E7-BC862C758002Q37811051-91582B9D-F4A3-4022-A42D-43C70EBB0180Q37894687-65ABC50C-47B0-4E81-A20A-F80F3324B07AQ37982150-100364BE-2F35-4BE1-9801-07780BCC9015Q38048823-82CEE6CF-8E74-446D-9840-BDE27B64242EQ38063552-94E55D34-7747-4B7D-B67A-BDB6C395EC9FQ38129947-7E2A50C1-E94F-4E89-8105-98BFF43BFEE8Q38184849-D99BFE91-3879-4D63-80E8-28C6C567EA22Q38203911-4E5DB793-6438-40C2-8639-065069E63027Q38251141-9CD2A87B-1AB4-431B-9025-0C284636D06FQ38372571-EEF82A82-1166-4C35-91A5-D4B23E36901B
P2860
A systematic review of intravesical bacillus Calmette-Guérin plus transurethral resection vs transurethral resection alone in Ta and T1 bladder cancer.
description
2001 nî lūn-bûn
@nan
2001 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
A systematic review of intrave ...... e in Ta and T1 bladder cancer.
@ast
A systematic review of intrave ...... e in Ta and T1 bladder cancer.
@en
type
label
A systematic review of intrave ...... e in Ta and T1 bladder cancer.
@ast
A systematic review of intrave ...... e in Ta and T1 bladder cancer.
@en
prefLabel
A systematic review of intrave ...... e in Ta and T1 bladder cancer.
@ast
A systematic review of intrave ...... e in Ta and T1 bladder cancer.
@en
P2093
P2860
P1433
P1476
A systematic review of intrave ...... ne in Ta and T1 bladder cancer
@en
P2093
P2860
P304
P356
10.1046/J.1464-410X.2001.02306.X
P577
2001-08-01T00:00:00Z